Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
about
Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBDOptimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel diseaseExposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairsBrazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liverCurrent stage in inflammatory bowel disease: What is next?Therapeutic drug monitoring in inflammatory bowel diseaseThiopurine monitoring in children with inflammatory bowel disease: a systematic reviewUse of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fictionRac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine TherapyPharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UseThe Role of Laboratory Tests in Crohn's DiseaseThiopurines and inflammatory bowel disease: Current evidence and a historical perspectiveOptimizing the use of thiopurines in inflammatory bowel diseaseMaintenance therapy with dose-adjusted 6-mercaptopurine in idiopathic pulmonary hemosiderosisLack of effect of intravenous azathioprine on time to respond for steroid treated Crohn's diseaseLeucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideMeasurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseUtilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel diseaseGene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acidAssociation between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysisPediatric Inflammatory Bowel Disease.Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease.Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendationsLong term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.Incidence, timing, and risk factors of azathioprine hepatotoxicosis in dogs.6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategiesMonitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel diseaseRoutine use of thiopurines in maintaining remission in pediatric Crohn's disease.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentHow to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport.Recent advances in inflammatory bowel disease.Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.Increasing relevance of pharmacogenetics of drug metabolism in clinical practice.Pharmacogenetics in clinical practice: considerations for testing.Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people.
P2860
Q24616161-0E6A4DEB-4E2B-4BFD-99FF-76BE00DB0C86Q24631869-6BCDE441-B220-442B-B415-D445CF226F39Q24678651-5BCFF42C-6926-4D1C-A3D2-7B5CF2A4E603Q26766699-4136D83C-BDA5-4BDC-B1AB-B7AC9649EFF6Q26777429-D736F7CA-38DD-4845-8554-C06EA964006CQ26852729-1AECA687-1FFD-48C4-8995-481A0893CE7EQ26859122-59C6EFA4-18A5-45D6-9CEB-61B7D8A0D0ACQ26996946-22944D58-ECAF-4573-B13E-008412A56948Q27023839-15247C1F-DEB3-452C-ABC7-A9525364AA91Q28067937-CD124362-CF83-41A1-8A62-A07E3C47BEB8Q28068930-7FD2CC78-A822-47BB-833B-F971BA38C0DBQ28075045-D615B605-9047-4C4E-816E-A8133142E651Q28079644-1BAC9B7F-C5C3-4DF1-8EF9-D06CE3739FE8Q28082687-01F7FB9A-BC40-424F-A465-4CF0AF36E442Q28299223-B58D3EA8-D4E1-4D13-BE43-E23D6107AF68Q28348579-C6E0A05D-7080-480F-8C4D-2ED15A7E5816Q28361611-6B8BD67F-908C-4C5D-806C-4783FCCD2DC2Q28361615-1AF44B5B-99FB-4F8F-B37C-6EE09F20D353Q28362619-A08A4E50-7D12-4422-863B-F8345CC385FFQ28486322-DF3754A3-C5FF-478B-9657-5EE31578AAF1Q28538238-03A7A879-E595-405F-9939-7E79F83F3CCCQ28544873-3A73A312-0C76-46D8-BAD0-0F474F269B35Q30240594-282F8CDD-077D-449B-9331-F15A0537C5A0Q30492009-5619E22A-B607-4A3F-A63B-B3B3DEA3FCA4Q33335841-7EDC7BE6-9083-45EB-89F5-F718CB445A21Q33385516-0133C8B4-8449-43F4-8E3F-B94323E859B9Q33393356-610630EE-0CDB-4E6F-ABA8-A7248CB11AC9Q33420121-0D1545F2-4F36-47A0-ADD5-57ED8FFB8971Q33436894-8D290A1B-029E-44B0-AAC5-6E9428573D4AQ33654733-2034B0AD-9E40-47AC-92C0-80CFDE6324A5Q33758469-27EFB5A9-A2E5-4341-82CE-4CB9F0C7C78EQ33941619-CF22A0DB-C121-48DB-B6E8-BF9D2D17B52BQ33958703-F8191488-61B5-481C-98E4-CDF1E1EF5561Q34073191-FD768F28-809E-4732-BFD5-190BCDE20316Q34093093-55846436-26F9-49FF-8221-52E3254DF03CQ34188405-7B95E278-E00D-4DB9-AAE5-77D89FE57189Q34421471-5852A3D3-7F66-4307-927B-5F8E58D56E37Q34447018-A62D2437-D305-4A69-BFB5-036232F89573Q34499056-9EC6A2D6-C21A-4136-80F8-68848963FBD4Q34522550-255D730D-2B34-4173-8E21-911AF97BDAE3
P2860
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacogenomics and metabolit ...... in inflammatory bowel disease.
@ast
Pharmacogenomics and metabolit ...... in inflammatory bowel disease.
@en
type
label
Pharmacogenomics and metabolit ...... in inflammatory bowel disease.
@ast
Pharmacogenomics and metabolit ...... in inflammatory bowel disease.
@en
prefLabel
Pharmacogenomics and metabolit ...... in inflammatory bowel disease.
@ast
Pharmacogenomics and metabolit ...... in inflammatory bowel disease.
@en
P2093
P1433
P1476
Pharmacogenomics and metabolit ...... in inflammatory bowel disease.
@en
P2093
Dubinsky MC
Seidman EG
P304
P356
10.1016/S0016-5085(00)70140-5
P407
P577
2000-04-01T00:00:00Z